Clinical trial • Phase III • Dermatology
Clinical trial in Malignant melanoma
Phase III trial for Malignant melanoma. 4 participants.
Overview
- Trial Therapeutic Area
- Dermatology
- Trial Disease
- Malignant melanoma
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 02-07-2024
- First CTIS Authorization Date
- 14-08-2024
Trial design
Phase III trial across 1 site in Belgium.
- Target Sample Size
- 4
- Trial Duration For Participant
- 1463
Eligibility
Recruits 4 Vulnerable population not selected; no consent or assent handling details provided in the record..
- Vulnerable Population
- Vulnerable population not selected; no consent or assent handling details provided in the record.
Recruitment
- Planned Sample Size
- 4
- Recruitment Window Months
- 48
- Consent Approach
- Informed consent approach not provided in the available record; no details on assent, age-specific documents, or languages available.
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 4
Belgium
- Earliest CTIS Part Ii Submission Date
- 02-08-2024
- Latest Decision Or Authorization Date
- 14-08-2024
- Processing Time Days
- 12
- Number Of Sites
- 1
- Number Of Participants
- 4
Sites
- Site Name
- UZ Leuven
- Department Name
- Oncology
- Principal Investigator Name
- Oliver Bechter
- Principal Investigator Email
- oliver.bechter@uzleuven.be
- Contact Person Name
- Oliver Bechter
- Contact Person Email
- oliver.bechter@uzleuven.be
- Number Of Participants
- 4
Sponsor
Primary sponsor
- Full Name
- UZ Leuven
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Belgium
Related trials
Other published trials that may interest you.
- (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE for Malignant melanoma
- CEMIPLIMAB, FIANLIMAB for Malignant melanoma
- Tildrakizumab for Chronic spontaneous urticaria
- BARZOLVOLIMAB for Chronic spontaneous urticaria
- BIMEKIZUMAB for Plaque psoriasis | Psoriasis